On Tuesday, Following U.S. Stocks were among the “Top Losers”: BioScrip, (NASDAQ:BIOS), EXCO Resources, (NYSE:XCO), AcelRx Pharmaceuticals, (NASDAQ:ACRX), Halcón Resources, (NYSE:HK)

• BioScrip Inc. (NASDAQ:BIOS)’s with shares dwindled -16.16%, closed at $3.6, hitting new 5252-week low of $3.59.

• EXCO Resources Inc. (NYSE:XCO), with shares declined -10.11%, settled at $1.60.

• AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), with shares dipped -15.70%, and closed at $4.64, hitting new 52-week low of $4.63.

• Halcón Resources Corporation (NYSE:HK), dropped -10.17%, and closed at $1.59.

Latest NEWS regarding these Stocks are depicted underneath:

BioScrip Inc. (NASDAQ:BIOS)

BioScrip Inc. (BIOS), declared the sale of $62.5 million in Series A Convertible Preferred Stock (“Preferred Stock”) to Coliseum Capital Administration, LLC (“Coliseum Capital”) and associated funds. The Preferred Stock is convertible into 12,088,975 shares of BioScrip’s ordinary stock at a conversion price of $5.17 per share, which was the closing price of BioScrip’s ordinary stock on the NASDAQ Global Market on March 6, 2015. Dividends on the Preferred Stock will be payable quarterly at an annual rate of 8.5% if paid in cash or 11.5% if accrued. As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock. Warrants for 1.8 million shares are exercisable at $5.295 per share and warrants for 1.8 million shares are exercisable at $6.596 per share.

In addition, BioScrip intends to conduct a registered rights offering to allow all of BioScrip’s existing stockholders of record, on a date to be determined by the Board, the non-transferable right to purchase their pro rata share of $20.0 million of Preferred Stock and warrants on the same terms as the accomplished private placement to Coliseum Capital. Coliseum Capital and its associates will not take part in the rights offering. Additional details regarding the anticipated rights offering will be comprised of in the Corporation’s Form S-3, which it intends to file with the Securities and Exchange Commission.

BioScrip, Inc. is a leading national provider of infusion and home care administration solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services.

EXCO Resources Inc. (NYSE:XCO)

Formerly on February 25, EXCO Resources Inc. (XCO), declared that it has filed a post-effective amendment to its existing automatic shelf registration statement, filed with the Securities and Exchange Commission (the “SEC”) on January 30, 2014 (the “Original Registration Statement”), related to the resale of shares of EXCO’s ordinary stock held by certain selling shareholders. EXCO filed the Original Registration Statement for the resale of shares held by the Selling Shareholders who either attained their shares in a private transaction and/or are considered associates of EXCO.

The Original Registration Statement was filed as an automatic shelf registration statement. Due to the recent decline in the trading price of EXCO’s ordinary stock, EXCO did not meet the requirements to maintain an automatic shelf registration statement at the time EXCO filed its Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Form 10-K”). Accordingly, EXCO filed a post-effective amendment to the Original Registration Statement to convert the Original Registration Statement to a non-automatic shelf registration statement (the “Amended Registration Statement”) which, when declared effective by the SEC, will permit the Selling Shareholders to resell shares following the Amended Registration Statement. EXCO filed the Amended Registration Statement to comply with the terms of a registration rights contract between EXCO and the Selling Shareholders. The SEC has not yet declared the Amended Registration Statement effective.

To EXCO’s knowledge, the Selling Shareholders have not expressed an intent to sell any of the Shares in the immediate future. EXCO has not and will not receive any proceeds from the sale of Shares under the Amended Registration Statement.

EXCO Resources, Inc. is an oil and natural gas exploration, exploitation, development and production corporation headquartered in Dallas, Texas with principal operations in Texas, North Louisiana and Appalachia.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. (ACRX), stated financial results for the three and twelve months ended December 31, 2014.

Fourth Quarter 2014 Financial Results:

Net loss for the fourth quarter of 2014 was $13.8 million, or $0.32 basic and diluted net loss per share, contrast to $17.8 million net revenue, or $0.41 basic net revenue per share and $0.39 diluted net revenue per share, for the fourth quarter of 2013.

Net loss in the fourth quarter as contrast to net revenue in the fourth quarter last year was primarily due to the receipt of a $30.0 million upfront payment under the partnership contract with Grunenthal, of which $27.4 million was recognized as proceed in the fourth quarter of 2013. In the fourth quarter of 2014, operating expenses of $12.0 million raised by $4.4 million from $7.6 million in the fourth quarter of 2013, primarily due to research and development activities to support resubmission of the Zalviso NDA, and an raise in headcount and related expenses in preparation for the potential commercialization of Zalviso.

During the fourth quarter of 2014, AcelRx recognized $226,000 of formerly deferred proceed under the partnership contract with Grunenthal. During the fourth quarter of 2013, in addition to the $27.4 million in proceed recognized under the Grunenthal collaboration, AcelRx also recognized proceed of $237,000 resulting from reimbursement for work accomplished under a research grant from the U.S. Army for development of ARX-04. Work under this research grant was accomplished in the fourth quarter of 2013.

Research and development expenses for the fourth quarter 2014 were $7.3 million, contrast to $4.3 million for the fourth quarter 2013. The raise was primarily due to activities to support the resubmission of the Zalviso NDA, build-out of the Medical Affairs team and continued development work on ARX-04.

General and administrative expenses were $4.7 million for the fourth quarter of 2014, contrast to $3.3 million for the fourth quarter of 2013. The raise was primarily due to activities in support of the potential commercialization of Zalviso.

Zalviso is an investigational pre-programmed, non-invasive system to allow hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical corporation focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx’s lead product candidate, Zalviso, is designed to improve the administration of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device.

Halcón Resources Corporation (NYSE:HK)

Formerly on February 25, Halcón Resources Corporation (HK), declared its fourth quarter and full year 2014 results. Halcon generated total proceeds of $239.5 million for the quarter ended December 31, 2014. Proceeds for the full year 2014 totaled $1,148.3 million, an raise of 15% contrast to the full year 2013.

Production for the three months and full year ended December 31, 2014 was 46,076 barrels of oil equivalent per day (Boe/d) and 42,107 Boe/d, respectively. The Corporation stated full year 2014 production above its guidance range. Production was comprised of 81% oil, 9% natural gas liquids (NGLs) and 10% natural gas for the quarter and 83% oil, 7% NGLs and 10% natural gas for the year.

Counting the influence of hedges, Halcon realized 105% of the average NYMEX oil price, 35% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price during the fourth quarter 2014. For the full year 2014, counting the influence of hedges, the Corporation realized 91% of the average NYMEX oil price, 36% of the average NYMEX oil price for NGLs and 94% of the average NYMEX natural gas price.

Total operating costs per unit, after adjusting for selected items (see Selected Operating Data table for additional information), reduced by 23% to $21.27 per Boe during the three months ended December 31, 2014, contrast to the same period of 2013. Total operating costs per unit for the full year, after adjusting for selected items (see Selected Operating Data table for additional information), were $24.14 per Boe, representing a decrease of 17% as compared to 2013.

After adjusting for selected items primarily related to the non-cash influence of derivatives and non-cash impairment charges (see Selected Item Review and Reconciliation table for additional information), net revenue was $20.6 million, or $0.05 per diluted share, and $71.7 million, or $0.17 per diluted share, for the quarter and full year ended December 31, 2014, respectively. Halcon stated net revenue accessible to ordinary stockholders of $247.3 million, or $0.48 per diluted share for the fourth quarter and $282.9 million, or $0.59 per diluted share for the year.

Halcon Resources Corporation is an independent energy corporation engaged in the attainment, production, exploration and development of onshore oil and natural gas properties in the United States.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content of this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.